Overview
Raised: $206,921
Rolling Commitments ($USD)
12/30/2020
$1,095
336
2017
Healthcare & Pharmaceuticals
Biotech
B2B/B2C
Medium
Low
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$415 |
$415 |
| ||
| ||
Net Income |
$-34,500 |
$-22,200 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$0 |
$0 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$500 |
$500 |
Short-Term Debt |
$35,000 |
$22,700 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$35,000 |
$22,700 |
Raise History
Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Quorum X Diagnostics | 04/29/2022 | Wefunder | $25,000,000 | $0 | SAFE | Not Funded | RegCF |
Quorum X Diagnostics | 12/03/2020 | Wefunder | $2,750,000 | $206,921 | SAFE | Funded | RegCF |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Founder Profile
Dr. Maria Nagy Talks At-Home Antigen Tests for COVID-19
As all eyes are on vaccines and testing for COVD-19, Quorum X Diagnostics pivoted from working on a Fast Test for Pseudomonal Pneumonia. Now, under the leadership of Dr. Maria Nagy, the team is working to bring to market an at-home COVID-19 antigen test. To make this possible, the team is currently raising funds via Wefunder.
We sat down with Maria to learn more about how she plans to allocate funds, who makes up her impressive team, and more-